The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...

Viking Therapeutics Inc.’s worst stock drop in nine years has handed traders betting against the company a gain big enough to ...

Viking Therapeutics Inc. plunged in early trading on Tuesday after its experimental obesity pill disappointed in a mid-stage ...

Mizuho's Jared Holz joins 'Fast Money' to talk Viking Therapeutics' massive stock drop on new obesity pill data.

The results could reinforce the dominance of Eli Lilly and Novo Nordisk in the booming market for weight loss and diabetes ...

Viking Therapeutics' stock recently tanked after reporting clinical trial results for an oral anti-obesity candidate. The ...

We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.

Viking Therapeutics, Inc.'s VK2735 trial results disappointed, yet long-term potential in the obesity market makes the stock ...

Viking Therapeutics (VKTX) shares crashed nearly 29% in todays trade after the companys much-anticipated weight-loss pill ...

Citi analyst David Lebowitz maintained a Hold rating on Viking Therapeutics today and set a price target of $29.00. The company’s shares closed today at $24.36. Take advantage of TipRanks Premium at ...